Is Halozyme Therapeutics, Inc. (HALO) Stock a Bad Value Wednesday?

A rating of 54 puts Halozyme Therapeutics, Inc. (HALO) near the top of the Healthcare sector according to InvestorsObserver. Halozyme Therapeutics, Inc.'s score of 54 means that it ranks higher than 54% of stocks in the sector. In addition, its overall score of 48 ranks it higher than 48% of all stocks.

HALO has an Overall Score of 48. Find out what this means to you and get the rest of the rankings on HALO!

See Full HALO Report

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies in the healthcare sector can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the best stocks in that sector. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Halozyme Therapeutics, Inc. Stock Today?

Halozyme Therapeutics, Inc. (HALO) stock is trading at $38.83 as of 11:48 AM on Wednesday, Oct 20, an increase of $0.07, or 0.18% from the previous closing price of $38.76. Volume today is less active than usual. So far 232,921 shares have traded compared to average volume of 790,079 shares. The stock has traded between $38.28 and $39.03 so far today. Click Here to get the full Stock Report for Halozyme Therapeutics, Inc. stock.